Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 65Not yet recruiting 39Completed 30Active not recruiting 27Terminated 12Withdrawn 2Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Head & Neck 1

Conditions

Solid Tumor 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 13Specimen Handling 12Cyclophosphamide 10fludarabine 9Radiotherapy 9Biopsy 8atezolizumab 7Nivolumab 7Radiation 6Prednisone 4Gemcitabine 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4ALT-803 4lenvatinib 3fludarabine phosphate 3avelumab 3aldesleukin 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3Paclitaxel 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × tislelizumab × 1 year × Clear all
NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

West China Hospital

Phase 2 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡